APO Research
Talk to an analyst

APO RESEARCH · REPORT

Flu Vaccine

Influenza vaccines, also known as flu shots, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. Most provide modest to high protection against influenza; however, each year this varies. Evidence in adults over 65 years old is poor. They decrease the number of missed days of work by a half day on average. Vaccinating children may protect those around them.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Influenza vaccines, also known as flu shots, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. Most provide modest to high protection against influenza; however, each year this varies. Evidence in adults over 65 years old is poor. They decrease the number of missed days of work by a half day on average. Vaccinating children may protect those around them.

Selected research

Market Structure

Global Flu Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025186 pages

Choose your research edition.

Industry ResearchFlu Vaccine Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Flu Vaccine Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Flu Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Flu Vaccine Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Flu Vaccine Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Influenza vaccines, also known as flu shots, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. Most provide modest to high protection against influenza; however, each year this varies. Evidence in adults over 65 years old is poor. They decrease the number of missed days of work by a half day on average. Vaccinating children may protect those around them.

Global Flu Vaccine key players include Sanofi Pasteur, CSL, GSK, etc. Global top three manufacturers hold a share over 75%.

North America is the largest market, with a share about 40%, followed by Europe, and Asia-Pacific, both have a share about 45 percent.

Read the full market overview

In terms of product, Quadrivalent Influenza Vaccine is the largest segment, with a share nearly 85%. And in terms of application, the largest application is For Adults and Children over 3 years, followed by For Children (6 months to 3 years).

This report provides an overview of the global Flu Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Flu Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Flu Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Flu Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Flu Vaccine Segment by Company

Sanofi Pasteur

CSL

GSK

Mylan

Hulan Bio

AstraZeneca

CCBIO

Flu Vaccine Segment by Type

Trivalent Influenza Vaccine

Quadrivalent Influenza Vaccine

Flu Vaccine Segment by Application

For Children (6 months to 3 years)

For Adults and Children over 3 years

Flu Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Flu Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Flu Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Flu Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Flu Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Flu Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Flu Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Flu Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Flu Vaccine Industry Trends Table 2. Flu Vaccine Industry Drivers Table 3. Flu Vaccine Industry Opportunities and Challenges Table 4. Flu Vaccine Industry Restraints Table 5. Global Flu Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Flu Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Flu Vaccine Sales by Manufacturers (M Doses) & (2021-2026) Table 8. Global Flu Vaccine Sales Market Share by Manufacturers Table 9. Global Flu Vaccine Average Sales Price (US$/Dose) of Manufacturers (2021-2026) Table 10. Global Flu Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Flu Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Flu Vaccine Manufacturers, Product Type & Application Table 13. Global Flu Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Flu Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Trivalent Influenza Vaccine Table 17. Major Manufacturers of Quadrivalent Influenza Vaccine Table 18. Global Flu Vaccine Sales by Type 2021 VS 2025 VS 2032 (M Doses) Table 19. Global Flu Vaccine Sales by Type (2021-2026) & (M Doses) Table 20. Global Flu Vaccine Sales by Type (2027-2032) & (M Doses) Table 21. Global Flu Vaccine Sales Market Share by Type (2021-2026) Table 22. Global Flu Vaccine Sales Market Share by Type (2027-2032) Table 23. Global Flu Vaccine Revenue by Type 2021 VS 2025 VS 2032 (M Doses) Table 24. Global Flu Vaccine Revenue by Type (2021-2026) & (M Doses) Table 25. Global Flu Vaccine Revenue by Type (2027-2032) & (M Doses) Table 26. Global Flu Vaccine Revenue Market Share by Type (2021-2026) Table 27. Global Flu Vaccine Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of For Children (6 months to 3 years) Table 29. Major Manufacturers of For Adults and Children over 3 years Table 30. Global Flu Vaccine Sales by Application 2021 VS 2025 VS 2032 (M Doses) Table 31. Global Flu Vaccine Sales by Application (2021-2026) & (M Doses) Table 32. Global Flu Vaccine Sales by Application (2027-2032) & (M Doses) Table 33. Global Flu Vaccine Sales Market Share by Application (2021-2026) Table 34. Global Flu Vaccine Sales Market Share by Application (2027-2032) Table 35. Global Flu Vaccine Revenue by Application 2021 VS 2025 VS 2032 (M Doses) Table 36. Global Flu Vaccine Revenue by Application (2021-2026) & (M Doses) Table 37. Global Flu Vaccine Revenue by Application (2027-2032) & (M Doses) Table 38. Global Flu Vaccine Revenue Market Share by Application (2021-2026) Table 39. Global Flu Vaccine Revenue Market Share by Application (2027-2032) Table 40. Global Flu Vaccine Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Table 41. Global Flu Vaccine Sales by Region (2021-2026) & (M Doses) Table 42. Global Flu Vaccine Sales Market Share by Region (2021-2026) Table 43. Global Flu Vaccine Sales Forecasted by Region (2027-2032) & (M Doses) Table 44. Global Flu Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Flu Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Doses) Table 46. North America Flu Vaccine Sales by Country (2021-2026) & (M Doses) Table 47. North America Flu Vaccine Sales by Country (2027-2032) & (M Doses) Table 48. Europe Flu Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Doses) Table 49. Europe Flu Vaccine Sales by Country (2021-2026) & (M Doses) Table 50. Europe Flu Vaccine Sales by Country (2027-2032) & (M Doses) Table 51. Asia Pacific Flu Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Doses) Table 52. Asia Pacific Flu Vaccine Sales by Country (2021-2026) & (M Doses) Table 53. Asia Pacific Flu Vaccine Sales by Country (2027-2032) & (M Doses) Table 54. South America, Middle East and Africa Flu Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Doses) Table 55. South America, Middle East and Africa Flu Vaccine Sales by Country (2021-2026) & (M Doses) Table 56. South America, Middle East and Africa Flu Vaccine Sales by Country (2027-2032) & (M Doses) Table 57. Global Flu Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Flu Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Flu Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Flu Vaccine Revenue Market Share by Region (2021-2026) Table 61. Global Flu Vaccine Revenue Market Share by Region (2027-2032) Table 62. Sanofi Pasteur Company Information Table 63. Sanofi Pasteur Business Overview Table 64. Sanofi Pasteur Flu Vaccine Sales (M Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Sanofi Pasteur Flu Vaccine Product Portfolio Table 66. Sanofi Pasteur Recent Development Table 67. CSL Company Information Table 68. CSL Business Overview Table 69. CSL Flu Vaccine Sales (M Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. CSL Flu Vaccine Product Portfolio Table 71. CSL Recent Development Table 72. GSK Company Information Table 73. GSK Business Overview Table 74. GSK Flu Vaccine Sales (M Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. GSK Flu Vaccine Product Portfolio Table 76. GSK Recent Development Table 77. Mylan Company Information Table 78. Mylan Business Overview Table 79. Mylan Flu Vaccine Sales (M Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Mylan Flu Vaccine Product Portfolio Table 81. Mylan Recent Development Table 82. Hulan Bio Company Information Table 83. Hulan Bio Business Overview Table 84. Hulan Bio Flu Vaccine Sales (M Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Hulan Bio Flu Vaccine Product Portfolio Table 86. Hulan Bio Recent Development Table 87. AstraZeneca Company Information Table 88. AstraZeneca Business Overview Table 89. AstraZeneca Flu Vaccine Sales (M Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. AstraZeneca Flu Vaccine Product Portfolio Table 91. AstraZeneca Recent Development Table 92. CCBIO Company Information Table 93. CCBIO Business Overview Table 94. CCBIO Flu Vaccine Sales (M Doses), Price (US$/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. CCBIO Flu Vaccine Product Portfolio Table 96. CCBIO Recent Development Table 97. Key Raw Materials Table 98. Raw Materials Key Suppliers Table 99. Flu Vaccine Distributors List Table 100. Flu Vaccine Customers List Table 101. Research Programs/Design for This Report Table 102. Authors List of This Report Table 103. Secondary Sources Table 104. Primary Sources List of Figures Figure 1. Flu Vaccine Product Image Figure 2. Global Flu Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Flu Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Flu Vaccine Sales (2021-2032) & (M Doses) Figure 5. Global Flu Vaccine Average Price (US$/Dose) & (2021-2032) Figure 6. Global Top 5 and 10 Flu Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Trivalent Influenza Vaccine Image Figure 9. Quadrivalent Influenza Vaccine Image Figure 10. Global Flu Vaccine Sales by Type (2021 VS 2025 VS 2032) & (M Doses) Figure 11. Global Flu Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Flu Vaccine Sales Market Share by Type (2021-2032) Figure 13. Global Flu Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (M Doses) Figure 14. Global Flu Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Flu Vaccine Revenue Market Share by Type (2021-2032) Figure 16. For Children (6 months to 3 years) Image Figure 17. For Adults and Children over 3 years Image Figure 18. Global Flu Vaccine Sales by Application (2021 VS 2025 VS 2032) & (M Doses) Figure 19. Global Flu Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Flu Vaccine Sales Market Share by Application (2021-2032) Figure 21. Global Flu Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (M Doses) Figure 22. Global Flu Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Flu Vaccine Revenue Market Share by Application (2021-2032) Figure 24. North America Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 25. North America Flu Vaccine Sales Market Share by Country (2021-2032) Figure 26. U.S. Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 27. Canada Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 28. Mexico Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 29. Europe Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 30. Europe Flu Vaccine Sales Market Share by Country (2021-2032) Figure 31. Germany Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 32. France Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 33. U.K. Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 34. Italy Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 35. Netherlands Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 36. Asia Pacific Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 37. Asia Pacific Flu Vaccine Sales Market Share by Country (2021-2032) Figure 38. China Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 39. Japan Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 40. South Korea Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 41. Southeast Asia Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 42. India Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 43. Australia Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 44. South America, Middle East and Africa Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 45. South America, Middle East and Africa Flu Vaccine Sales Market Share by Country (2021-2032) Figure 46. Brazil Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 47. South Africa Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 48. Saudi Arabia Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 49. Turkey Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 50. Argentina Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 51. UAE Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 52. Egypt Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 53. Chile Flu Vaccine Sales and Growth Rate (2021-2032) & (M Doses) Figure 54. Global Flu Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Flu Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Flu Vaccine Revenue (2021-2032) & (US$ Million) Figure 57. North America Flu Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Flu Vaccine Revenue (2021-2032) & (US$ Million) Figure 59. Europe Flu Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Flu Vaccine Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Flu Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Flu Vaccine Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Flu Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Flu Vaccine Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Flu Vaccine Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Trivalent Influenza Vaccine
  • Quadrivalent Influenza Vaccine
Applications
  • For Children (6 months to 3 years)
  • For Adults and Children over 3 years
Companies covered
  • Sanofi Pasteur
  • CSL
  • GSK
  • Mylan
  • Hulan Bio
  • AstraZeneca
  • CCBIO

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Flu Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Flu Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Flu Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Flu Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Flu Vaccine Market Dynamics
  1. 2.1 Flu Vaccine Industry Trends
  2. 2.2 Flu Vaccine Industry Drivers
  3. 2.3 Flu Vaccine Industry Opportunities and Challenges
  4. 2.4 Flu Vaccine Industry Restraints
3 Flu Vaccine Market by Manufacturers
  1. 3.1 Global Flu Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Flu Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Flu Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Flu Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Flu Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Flu Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Flu Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Flu Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Flu Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Flu Vaccine Tier 1, Tier 2, and Tier 3
4 Flu Vaccine Market by Type
  1. 4.1 Flu Vaccine Type Introduction
  2. 4.1.1 Trivalent Influenza Vaccine
  3. 4.1.2 Quadrivalent Influenza Vaccine
  4. 4.2 Global Flu Vaccine Sales by Type
  5. 4.2.1 Global Flu Vaccine Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Flu Vaccine Sales by Type (2021-2032)
  7. 4.2.3 Global Flu Vaccine Sales Market Share by Type (2021-2032)
  8. 4.3 Global Flu Vaccine Revenue by Type
  9. 4.3.1 Global Flu Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Flu Vaccine Revenue by Type (2021-2032)
  11. 4.3.3 Global Flu Vaccine Revenue Market Share by Type (2021-2032)
5 Flu Vaccine Market by Application
  1. 5.1 Flu Vaccine Application Introduction
  2. 5.1.1 For Children (6 months to 3 years)
  3. 5.1.2 For Adults and Children over 3 years
  4. 5.2 Global Flu Vaccine Sales by Application
  5. 5.2.1 Global Flu Vaccine Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Flu Vaccine Sales by Application (2021-2032)
  7. 5.2.3 Global Flu Vaccine Sales Market Share by Application (2021-2032)
  8. 5.3 Global Flu Vaccine Revenue by Application
  9. 5.3.1 Global Flu Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Flu Vaccine Revenue by Application (2021-2032)
  11. 5.3.3 Global Flu Vaccine Revenue Market Share by Application (2021-2032)
6 Global Flu Vaccine Sales by Region
  1. 6.1 Global Flu Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Flu Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Flu Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Flu Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Flu Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Flu Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Flu Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Flu Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Flu Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Flu Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Flu Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Flu Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Flu Vaccine Revenue by Region
  1. 7.1 Global Flu Vaccine Revenue by Region
  2. 7.1.1 Global Flu Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Flu Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Flu Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Flu Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Flu Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Flu Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Flu Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Flu Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Flu Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Flu Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Flu Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Flu Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi Pasteur
  2. 8.1.1 Sanofi Pasteur Company Information
  3. 8.1.2 Sanofi Pasteur Business Overview
  4. 8.1.3 Sanofi Pasteur Flu Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Pasteur Flu Vaccine Product Portfolio
  6. 8.1.5 Sanofi Pasteur Recent Developments
  7. 8.2 CSL
  8. 8.2.1 CSL Company Information
  9. 8.2.2 CSL Business Overview
  10. 8.2.3 CSL Flu Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 CSL Flu Vaccine Product Portfolio
  12. 8.2.5 CSL Recent Developments
  13. 8.3 GSK
  14. 8.3.1 GSK Company Information
  15. 8.3.2 GSK Business Overview
  16. 8.3.3 GSK Flu Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GSK Flu Vaccine Product Portfolio
  18. 8.3.5 GSK Recent Developments
  19. 8.4 Mylan
  20. 8.4.1 Mylan Company Information
  21. 8.4.2 Mylan Business Overview
  22. 8.4.3 Mylan Flu Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mylan Flu Vaccine Product Portfolio
  24. 8.4.5 Mylan Recent Developments
  25. 8.5 Hulan Bio
  26. 8.5.1 Hulan Bio Company Information
  27. 8.5.2 Hulan Bio Business Overview
  28. 8.5.3 Hulan Bio Flu Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Hulan Bio Flu Vaccine Product Portfolio
  30. 8.5.5 Hulan Bio Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca Flu Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Flu Vaccine Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
  37. 8.7 CCBIO
  38. 8.7.1 CCBIO Company Information
  39. 8.7.2 CCBIO Business Overview
  40. 8.7.3 CCBIO Flu Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 CCBIO Flu Vaccine Product Portfolio
  42. 8.7.5 CCBIO Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Flu Vaccine Value Chain Analysis
  2. 9.1.1 Flu Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Flu Vaccine Production Mode & Process
  6. 9.2 Flu Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Flu Vaccine Distributors
  9. 9.2.3 Flu Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst